A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
← catalyst calendarSponsored by Jasper Therapeutics, Inc. (industry) · JSPR — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
67actual
Sites
19
Countries
Germany, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-26 | actual | When the study began enrolling |
| Primary completion | 2026-07-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-21 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Urticaria Chronic
Intervention
- Drug: Briquilimab
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of briquilimab
measured From signing the informed consent form through study completion (an average of one year)
Permalink · JSPR's whole pipeline · Catalyst calendar · Every registered study · What changed